Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series.

ABSTRACT:

Background

The rates of suspected allergic reactions to the first dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with an anaphylaxis incidence up to 2.5 per 10,000 individuals. Anaphylaxis in response to the first dose may be considered a contraindication to administration of the second dose, even though the second dose is necessary for optimal protection against severe disease. Many individuals with anaphylactic reactions to the first dose still want to receive a second dose. However, there are few published data to support the safety of administration of a second dose in this population.

Objective

The primary objective of this study was to determine the percentage of patients tolerating a second COVID-19 mRNA vaccine d

SUBMITTER: Iaboni A 

PROVIDER: S-EPMC9010013 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature